SCHEMBL1502191

SCHEMBL1502191

CC(C)n1cncc1-c1cccc(O)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.49
IDO1 P14902 2/20 0.45
TDO2 P48775 1/20 0.45
PIK3CD O00329 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44
PRKDC P78527 1/20 0.44
HSD17B1 P14061 4/20 0.43
HSD17B2 P37059 4/20 0.43
FYN P06241 8/20 0.42
MKNK1 Q9BUB5 1/20 0.42
METAP2 P50579 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CLK2 P49760 1/20 0.41
CLK3 P49761 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10981291 0.81 CLK2 (0.40) CYP17A1IDO1FYNMKNK1CYP3A4
SCHEMBL19868940 0.81 CYP11B1 (0.49) IDO1TDO2FYNCLK2CLK3
SCHEMBL1501843 0.80 IDO1 (0.66) CYP17A1IDO1TDO2HSD17B1HSD17B2
SCHEMBL1502348 0.79 BRD9 (0.52) CYP17A1IDO1TDO2FYNCYP3A4
SCHEMBL1501932 0.79 IDO1 (0.50) CYP17A1IDO1TDO2HSD17B1HSD17B2
SCHEMBL1949967 0.77 KDM5B (0.42) IDO1
SCHEMBL1501838 0.76 IDO1 (0.53) CYP17A1IDO1TDO2HSD17B1HSD17B2
SCHEMBL1501997 0.74 IDO1 (0.51) CYP17A1IDO1TDO2HSD17B1HSD17B2
SCHEMBL1501880 0.73 IDO1 (0.53) CYP17A1IDO1TDO2HSD17B1HSD17B2
SCHEMBL1501988 0.72 IDO1 (0.63) IDO1TDO2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 US disclosed
US-20140323740-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION (US) 2014-10-30 US disclosed
US-8748469-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2014-06-10 US disclosed
CN-102083429-B Ido inhibitors NEWLINK GENETICS 2014-05-28 CN disclosed
US-20110136796-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-06-09 US disclosed
CN-102083429-A Ido inhibitors NEWLINK GENETICS 2011-06-01 CN disclosed
EP-2291187-A2 IDO INHIBITORS Newlink Genetics (US) 2011-03-09 EP disclosed
WO-2009132238-A2 IDO INHIBITORS NEWLINK GENETICS (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323740-A1 IDO Inhibitors IDO1, IDO2, INMT CYP17A1 1022/4885IDO1 1/4885TDO2 4/4885
US-20110136796-A1 IDO Inhibitors IDO1, IDO2, INMT CYP17A1 1022/4885IDO1 1/4885TDO2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.